Life Sciences | Fieldfisher
Skip to main content
Select location

Why choose our Life Sciences lawyers?

Europe offers a world-class science base with a thriving ecosystem, which boasts a rich array of entities ranging from start-ups all the way up to some of the world's largest pharmaceutical companies.

During an unprecedented time of innovation, it is vital to have in place professional advisors that have the necessary capabilities to adapt just as rapidly and that can provide the right support and input exactly when and where it is needed.

Fieldfisher's focus on cross-departmental collaboration means that we are well placed to seamlessly provide multifaceted legal support. With a wealth of experience advising small and large entities alike, our expertise across key subsectors, including digital health, agrochemicals, cannabis and cell and gene therapy, means we deliver meaningful and impactful value to our clients.

Internationally, life sciences and healthcare remains a high priority sector for spending and investment in order to support growth and innovation at both a governmental and private financing level. Accordingly, it is critical for companies to pick the right advisors and here at Fieldfisher we are committed to delivering high-quality advice.

Fieldfisher is internationally recognised for its work in the regulatory environment and routinely advises on the implications of current and future regulation in the life sciences and healthcare industry. Continued technological and scientific advancement brings with it significant changes in both the regulatory and legislative landscape and forthcoming changes will require ongoing internal review and consultation in order to avoid avoidable complications and setbacks. 

Life Sciences Insights
Filter Media
See More
Key numbers
23
numbers
25
laptops
100
cranes
How can we help you?
All sectors All services
Our team can help you across the following areas:
Agrochemicals
Cannabis
Cell and gene therapy
Healthcare
Pharmaceuticals and Biotechnology
Medical Devices
Copyright and Database Rights
Trade Marks and Brands
Arbitration
Corporate Disputes
Web 3.0 and Distributed Ledger Technology
Notable deals
Advised Ultromics, a leader in AI enabled cardiovascular imaging solutions, on its Series B funding round
Fieldfisher advised UK headquartered MedTech company Ultromics on its Series B funding round led by the Blue Venture Fund with participation from Optum Ventures, GV, and existing investor Oxford Sciences Innovation, to help transform cardiac disease treatment.
Advising Roche Products Ltd on its contributions unlicensed medicines
Our Life Sciences team have continued to support oncology and ophthalmology medications, labelling Brexit and export control issues as the medical giant navigate new challenges.
What people say abut us....
Legal 500
Lorem ipsum odor amet, consectetuer adipiscing elit. Dictum imperdiet vivamus condimentum ad quis cubilia sodales quis. Condimentum facilisis potenti magnis nascetur id. Imperdiet consectetur ultricies hendrerit fringilla convallis commodo tellus. Ante primis class malesuada per at leo magna. Ut class tempus tempus; sollicitudin facilisi primis. Felis sem conubia congue varius mi. Urna fames class lacinia rhoncus erat senectus placerat. Nisl auctor convallis nascetur eu magnis class.
Chambers
Lorem ipsum odor amet, consectetuer adipiscing elit. Dictum imperdiet vivamus condimentum ad quis cubilia sodales quis. Condimentum facilisis potenti magnis nascetur id. Imperdiet consectetur ultricies hendrerit fringilla convallis commodo tellus. Ante primis class malesuada per at leo magna. Ut class tempus tempus; sollicitudin facilisi primis. Felis sem conubia congue varius mi. Urna fames class lacinia rhoncus erat senectus placerat. Nisl auctor convallis nascetur eu magnis class.Lorem ipsum odor amet, consectetuer adipiscing elit. Dictum imperdiet vivamus condimentum ad quis cubilia sodales quis. Condimentum facilisis potenti magnis nascetur id. Imperdiet consectetur ultricies hendrerit fringilla convallis commodo tellus. Ante primis class malesuada per at leo magna. Ut class tempus tempus; sollicitudin facilisi primis. Felis sem conubia congue varius mi. Urna fames class lacinia rhoncus erat senectus placerat. Nisl auctor convallis nascetur eu magnis class.
Key contacts
see full team

Fieldfisher Insights Hub

Subscribe Today!

Interested in recieving more updates about Life Sciences, use the link below to subscribe to the latest Fieldfisher legal insights. 

Subscribe now

Notable deals and highlights

  • Advising Roche Products Limited on its contributions unlicensed medicines for treatment for and help with management of the Covid-19 virus, including various aspects of the clinical trials processes. In addition to this, Our Life Sciences team have also continued to support oncology and ophthalmology medications, labelling Brexit and export control issues as the medical giant navigate new challenges. Our team also advised Roche Products on two research collaboration agreements.
  • Advised Ultromics, a leader in AI enabled cardiovascular imaging solutions, on its Series B funding round led by the Blue Venture Fund with participation from Optum Ventures, GV, and existing investor Oxford Sciences Innovation, to help transform cardiac disease treatment. Fieldfisher advised UK headquartered MedTech company Ultromics, a leader in AI enabled cardiovascular imaging solutions, on its Series B funding round led by the Blue Venture Fund with participation from Optum Ventures, GV, and existing investor Oxford Sciences Innovation, to help transform cardiac disease treatment.
  • We further advised Ultromics on complex contracts in relation to them winning a competition for a phase 3 and phase 4 grant sponsored by the NHS and related bodies to implement AI technology into the NHS and the deals generated a number of press articles:
  • Ultromics raises $33M in Series B funding to help transform cardiac disease treatment - Ultromics
  • Ultromics Raises $33M in Series B Funding to Help Transform Cardiac Disease Treatment (prnewswire.com)
  • Fieldfisher advises Ultromics on $33 million Series B funding | Fieldfisher
  •  Advised Synairgen in relation to a Phase III Clinical Trial for their interferon Beta therapeutic inhaled treatment for Covid-19. We advised Synairgen in relation to a Phase III Clinical Trial for their interferon Beta therapeutic inhaled treatment for covid-19, which completed on 10 February 2022. In addition to this, we also advised Synairgen on a major fundraising primarily intended to enable them to progress with the Phase III clinical trials, enrolling participants across multiple countries, and fund manufacturing and device scale-up activities. The transaction was one of largest public fundraisings in the biotech sector for several years and followed a £14 million fundraising Fieldfisher advised the company on in March 2020.

Latest Life Sciences news and views

view all insights
Get in touch
Hide